• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Enzalutamide, apalutamide, or darolutamide: are apples or bananas best for patients?

作者信息

Higano Celestia

机构信息

Division of Oncology, Department of Medicine, University of Washington and Fred Hutchinson Cancer Research Center, Seattle, WA, USA.

出版信息

Nat Rev Urol. 2019 Jun;16(6):335-336. doi: 10.1038/s41585-019-0186-2.

DOI:10.1038/s41585-019-0186-2
PMID:31040439
Abstract
摘要

相似文献

1
Enzalutamide, apalutamide, or darolutamide: are apples or bananas best for patients?恩杂鲁胺、阿帕鲁胺或达罗他胺：苹果还是香蕉对患者最有益？
Nat Rev Urol. 2019 Jun;16(6):335-336. doi: 10.1038/s41585-019-0186-2.
2
Comparative efficacy of apalutamide darolutamide and enzalutamide for treatment of non-metastatic castrate-resistant prostate cancer: A systematic review and network meta-analysis.阿帕鲁胺、达罗他胺和恩扎卢胺治疗去势抵抗性前列腺癌非转移性前列腺癌的疗效比较：系统评价和网络荟萃分析。
Urol Oncol. 2020 Nov;38(11):826-834. doi: 10.1016/j.urolonc.2020.03.022. Epub 2020 Jun 28.
3
Improvement in overall survival with Apalutamide, Darolutamide and Enzalutamide in patients with non-metastatic castration-resistant prostate cancer.阿帕鲁胺、达罗他胺和恩扎卢胺可改善非转移性去势抵抗性前列腺癌患者的总生存期。
Cancer Treat Res Commun. 2020;25:100205. doi: 10.1016/j.ctarc.2020.100205. Epub 2020 Aug 12.
4
Combining prostate cancer radiotherapy with therapies targeting the androgen receptor axis.将前列腺癌放疗与针对雄激素受体轴的疗法相结合。
Curr Oncol. 2019 Oct;26(5):e640-e650. doi: 10.3747/co.26.5005. Epub 2019 Oct 1.
5
Matching-Adjusted Indirect Comparison of Health-Related Quality of Life and Adverse Events of Apalutamide Versus Enzalutamide in Non-Metastatic Castration-Resistant Prostate Cancer.阿帕鲁胺与恩杂鲁胺用于非转移性去势抵抗性前列腺癌的健康相关生活质量和不良事件的匹配调整间接比较。
Adv Ther. 2020 Jan;37(1):512-526. doi: 10.1007/s12325-019-01157-4. Epub 2019 Dec 7.
6
Matching-Adjusted Indirect Comparison of the Efficacy of Apalutamide and Enzalutamide with ADT in the Treatment of Non-Metastatic Castration-Resistant Prostate Cancer.阿帕鲁胺和恩扎卢胺与 ADT 联合治疗去势抵抗性前列腺癌的非转移性疗效的匹配调整间接比较。
Adv Ther. 2020 Jan;37(1):501-511. doi: 10.1007/s12325-019-01156-5. Epub 2019 Dec 7.
7
Management of Nonmetastatic Castration-Resistant Prostate Cancer: Recent Advances and Future Direction.非转移性去势抵抗性前列腺癌的管理：最新进展与未来方向。
Curr Treat Options Oncol. 2019 Feb 11;20(2):14. doi: 10.1007/s11864-019-0611-z.
8
Pharmacokinetic Interactions Between Abiraterone, Apalutamide, Darolutamide or Enzalutamide and Antithrombotic Drugs: Prediction of Clinical Events and Review of Pharmacological Information.阿比特龙、阿帕鲁胺、达罗他胺或恩扎卢胺与抗血栓药物的药代动力学相互作用：临床事件预测及药理学信息综述。
Cardiovasc Drugs Ther. 2024 Aug;38(4):757-767. doi: 10.1007/s10557-023-07453-0. Epub 2023 May 1.
9
Advanced Androgen Blockage in Nonmetastatic Castration-resistant Prostate Cancer: An Indirect Comparison of Apalutamide and Enzalutamide.非转移性去势抵抗性前列腺癌的雄激素阻断治疗：阿帕鲁胺与恩扎卢胺的间接比较
Eur Urol Oncol. 2018 Aug;1(3):238-241. doi: 10.1016/j.euo.2018.04.004. Epub 2018 May 15.
10
Resistance to second-generation androgen receptor antagonists in prostate cancer.前列腺癌中第二代雄激素受体拮抗剂的耐药性。
Nat Rev Urol. 2021 Apr;18(4):209-226. doi: 10.1038/s41585-021-00438-4. Epub 2021 Mar 19.

引用本文的文献

1
Pharmacological class effects of anticancer drugs: opportunities for decreasing healthcare spending.抗癌药物的药理学类效应：降低医疗支出的机遇
BMJ Oncol. 2024 Jan 30;3(1):e000287. doi: 10.1136/bmjonc-2023-000287. eCollection 2024.
2
Circulating tumor DNA landscape and prognostic impact of acquired resistance to targeted therapies in cancer patients: a national center for precision medicine (PRISM) study.循环肿瘤 DNA 图谱及癌症患者靶向治疗获得性耐药的预后影响：国家精准医疗研究中心（PRISM）研究。
Mol Cancer. 2023 Nov 4;22(1):176. doi: 10.1186/s12943-023-01878-9.
3
Loss of LCMT1 and biased protein phosphatase 2A heterotrimerization drive prostate cancer progression and therapy resistance.
LCMT1 缺失和蛋白磷酸酶 2A 异三聚体的偏置驱动前列腺癌的进展和治疗抵抗。
Nat Commun. 2023 Aug 29;14(1):5253. doi: 10.1038/s41467-023-40760-6.
4
Discovery of ARD-2051 as a Potent and Orally Efficacious Proteolysis Targeting Chimera (PROTAC) Degrader of Androgen Receptor for the Treatment of Advanced Prostate Cancer.发现 ARD-2051 是一种有效的雄激素受体降解剂（PROTAC），可用于治疗晚期前列腺癌。
J Med Chem. 2023 Jul 13;66(13):8822-8843. doi: 10.1021/acs.jmedchem.3c00405. Epub 2023 Jun 29.
5
Assessment of real-world application of advanced prostate cancer management in Japan.日本晚期前列腺癌管理的真实世界应用评估。
Transl Androl Urol. 2022 Dec;11(12):1614-1617. doi: 10.21037/tau-22-765.
6
GSTM2 is a key molecular determinant of resistance to SG-ARIs.GSTM2 是对 SG-ARIs 产生耐药性的关键分子决定因素。
Oncogene. 2022 Sep;41(40):4498-4511. doi: 10.1038/s41388-022-02444-1. Epub 2022 Aug 29.
7
Androgen and oestrogen receptor co-expression determines the efficacy of hormone receptor-mediated radiosensitisation in breast cancer.雄激素和雌激素受体共表达决定了激素受体介导的乳腺癌放射增敏的疗效。
Br J Cancer. 2022 Sep;127(5):927-936. doi: 10.1038/s41416-022-01849-9. Epub 2022 May 26.
8
Treatment and trials in non-metastatic castration-resistant prostate cancer.非转移性去势抵抗性前列腺癌的治疗与试验。
Nat Rev Urol. 2021 Jul;18(7):433-442. doi: 10.1038/s41585-021-00470-4. Epub 2021 May 17.
9
Inferences About Drug Safety in Phase III Trials in Oncology: Examples From Advanced Prostate Cancer.肿瘤学 III 期临床试验中的药物安全性推断：晚期前列腺癌的实例。
J Natl Cancer Inst. 2021 May 4;113(5):553-561. doi: 10.1093/jnci/djaa134.
10
Comprehensive Analysis of AR Alterations in Circulating Tumor DNA from Patients with Advanced Prostate Cancer.全面分析晚期前列腺癌患者循环肿瘤 DNA 中的 AR 改变。
Oncologist. 2020 Apr;25(4):327-333. doi: 10.1634/theoncologist.2019-0115. Epub 2019 Nov 11.